Biogen Posts Double-Digit Profits, Has Cash to Burn [The Motley Fool]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: The Motley Fool
Spinal muscular atrophy drug Spinraza makes up for declines in the biotech's multiple sclerosis drug franchise. Drug-developer Biogen ( NASDAQ:BIIB ) reported a pretty strong earnings increase in the first quarter. While revenue growth wasn't as solid, investors appear to be giving management a pass, thanks to its explanations on why slowing first-quarter sales aren't a sign of future trouble. Biogen results: The raw numbers Metric Q4 2017 Q4 2016 Year-Over-Year Change Revenue $3.13 billion $2.81 billion 11% Income from operations $1.53 billion $1.02 billion 50% Earnings per share (EPS) $5.54 $3.46 60% Adjusted EPS $6.05 $5.20 16% Data source: Biogen. What happened with Biogen this quarter? Excluding the hemophilia drugs that were spun off last year, revenue was up an even more impressive 15% year over year. With multiple sclerosis pati
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis to hold first quarter 2024 financial results webcastPR Newswire
- Bepirovirsen for Chronic Hepatitis B Drug Pipeline Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032 [Yahoo! Finance]Yahoo! Finance
- n-Lorem Foundation Collaborates with Across Healthcare to Develop a Custom Submission Platform for Physicians of Nano-rare Patients [Yahoo! Finance]Yahoo! Finance
- n-Lorem Foundation Announces the Second Annual Nano-rare Patient Colloquium Will be Held on Oct. 30 & 31, 2024 [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating.MarketBeat
IONS
Earnings
- 2/21/24 - Beat
IONS
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- 4/16/24 - Form 144
- IONS's page on the SEC website